401 related articles for article (PubMed ID: 32844821)
1. Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2.
Nasir M; Perveen RA; Saha SK; Talha KA; Selina F; Islam MA
Mymensingh Med J; 2020 Jul; 29(3):747-754. PubMed ID: 32844821
[TBL] [Abstract][Full Text] [Related]
2. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
Li J; Zhang C; Wu Z; Wang G; Zhao H
Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
[TBL] [Abstract][Full Text] [Related]
3. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
[TBL] [Abstract][Full Text] [Related]
4. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis.
Shrestha DB; Budhathoki P; Khadka S; Shah PB; Pokharel N; Rashmi P
Virol J; 2020 Sep; 17(1):141. PubMed ID: 32972430
[TBL] [Abstract][Full Text] [Related]
5. Favipiravir, an antiviral for COVID-19?
Coomes EA; Haghbayan H
J Antimicrob Chemother; 2020 Jul; 75(7):2013-2014. PubMed ID: 32417899
[No Abstract] [Full Text] [Related]
6. Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.
Fu D; Cao R; Zhao L; Li W; Zhong W; Wen J
Crit Care; 2020 Sep; 24(1):578. PubMed ID: 32977854
[No Abstract] [Full Text] [Related]
7. An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.
McMahon JH; Lau JSY; Roney J; Rogers BA; Trubiano J; Sasadeusz J; Molton JS; Gardiner B; Lee SJ; Hoy JF; Cheng A; Peleg AY
Trials; 2020 Oct; 21(1):847. PubMed ID: 33050947
[TBL] [Abstract][Full Text] [Related]
8. A Review of SARS-CoV-2 and the Ongoing Clinical Trials.
Tu YF; Chien CS; Yarmishyn AA; Lin YY; Luo YH; Lin YT; Lai WY; Yang DM; Chou SJ; Yang YP; Wang ML; Chiou SH
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290293
[TBL] [Abstract][Full Text] [Related]
9. Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials.
Arab-Zozani M; Hassanipour S; Ghoddoosi-Nejad D
BMJ Open; 2020 Jul; 10(7):e039730. PubMed ID: 32737100
[TBL] [Abstract][Full Text] [Related]
10. A Favipiravir-induced Fever in a Patient with COVID-19.
Kurita T; Ishida K; Muranaka E; Sasazawa H; Mito H; Yano Y; Hase R
Intern Med; 2020; 59(22):2951-2953. PubMed ID: 33191372
[TBL] [Abstract][Full Text] [Related]
11. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
12. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Duvignaud A; Lhomme E; Pistone T; Onaisi R; Sitta R; Journot V; Nguyen D; Peiffer-Smadja N; Crémer A; Bouchet S; Darnaud T; Poitrenaud D; Piroth L; Binquet C; Michel JF; Lefèvre B; Lebeaux D; Lebel J; Dupouy J; Roussillon C; Gimbert A; Wittkop L; Thiébaut R; Orne-Gliemann J; Joseph JP; Richert L; Anglaret X; Malvy D;
Trials; 2020 Oct; 21(1):846. PubMed ID: 33050924
[TBL] [Abstract][Full Text] [Related]
13. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.
Kaptein SJF; Jacobs S; Langendries L; Seldeslachts L; Ter Horst S; Liesenborghs L; Hens B; Vergote V; Heylen E; Barthelemy K; Maas E; De Keyzer C; Bervoets L; Rymenants J; Van Buyten T; Zhang X; Abdelnabi R; Pang J; Williams R; Thibaut HJ; Dallmeier K; Boudewijns R; Wouters J; Augustijns P; Verougstraete N; Cawthorne C; Breuer J; Solas C; Weynand B; Annaert P; Spriet I; Vande Velde G; Neyts J; Rocha-Pereira J; Delang L
Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26955-26965. PubMed ID: 33037151
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.
Hassanipour S; Arab-Zozani M; Amani B; Heidarzad F; Fathalipour M; Martinez-de-Hoyo R
Sci Rep; 2021 May; 11(1):11022. PubMed ID: 34040117
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapy in COVID-19; A narrative review for emergency providers.
Mehta N; Mazer-Amirshahi M; Alkindi N; Pourmand A
Am J Emerg Med; 2020 Jul; 38(7):1488-1493. PubMed ID: 32336586
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
[TBL] [Abstract][Full Text] [Related]
18. Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019.
Hase R; Kurata R; Ishida K; Kurita T; Muranaka E; Mito H
Intern Med; 2020 Sep; 59(18):2327-2329. PubMed ID: 32727996
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
Sanders JM; Monogue ML; Jodlowski TZ; Cutrell JB
JAMA; 2020 May; 323(18):1824-1836. PubMed ID: 32282022
[TBL] [Abstract][Full Text] [Related]
20. Use of Remdesivir in the Management of COVID-19: A Systematic Review on Current Evidences.
Nasir M; Talha KA; Islam T; Saha SK; Selina F; Parveen RA
Mymensingh Med J; 2020 Apr; 29(2):481-487. PubMed ID: 32506110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
